It was Johnson & Johnson’s turn to take center stage at ASCO Saturday morning, fleshing out the promising data that it accumulated in a Phase II study of daratumumab for treatment-resistant multiple myeloma.

…read more

Source: J&J builds promising case for multiple myeloma competitor daratumumab